CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $152,634,215 | +59.9% | 5,132,287 | -3.1% | 1.98% | +64.6% |
| Q2 2023 | $95,471,546 | +12.4% | 5,298,088 | +0.2% | 1.20% | +1.1% |
| Q1 2023 | $84,949,675 | -17.5% | 5,289,519 | -6.0% | 1.19% | -22.3% |
| Q4 2022 | $102,932,815 | -6.9% | 5,624,744 | -0.1% | 1.54% | -8.4% |
| Q3 2022 | $110,612,000 | +8.3% | 5,631,958 | +2.9% | 1.68% | +1.3% |
| Q2 2022 | $102,099,000 | -5.9% | 5,474,459 | +10.7% | 1.65% | +24.1% |
| Q1 2022 | $108,521,000 | -20.3% | 4,944,013 | +3.1% | 1.33% | -4.1% |
| Q4 2021 | $136,187,000 | +115.8% | 4,793,638 | +59.9% | 1.39% | +85.8% |
| Q3 2021 | $63,119,000 | +23.7% | 2,998,512 | +10.7% | 0.75% | +10.7% |
| Q2 2021 | $51,043,000 | +66.7% | 2,707,825 | +35.1% | 0.68% | +49.6% |
| Q1 2021 | $30,616,000 | +49.2% | 2,003,688 | +37.8% | 0.45% | +36.6% |
| Q4 2020 | $20,515,000 | +49.6% | 1,453,966 | +66.2% | 0.33% | +17.8% |
| Q3 2020 | $13,709,000 | -11.8% | 874,842 | -1.3% | 0.28% | -25.7% |
| Q2 2020 | $15,536,000 | – | 886,762 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |